Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer.

Citation data:

Oncotarget, ISSN: 1949-2553, Vol: 8, Issue: 4, Page: 6446-6460

Publication Year:
2017
Captures 10
Readers 10
Social Media 1
Tweets 1
Citations 3
Citation Indexes 3
PMID:
28031536
DOI:
10.18632/oncotarget.14119
Author(s):
Montoya, Alexa, Amaya, Clarissa N, Belmont, Andres, Diab, Nabih, Trevino, Richard, Villanueva, Geri, Rains, Steven, Sanchez, Luis A, Badri, Nabeel, Otoukesh, Salman, Khammanivong, Ali, Liss, Danielle, Baca, Sarah T, Aguilera, Renato J, Dickerson, Erin B, Torabi, Alireza, Dwivedi, Alok K, Abbas, Aamer, Chambers, Karinn, Bryan, Brad A, Nahleh, Zeina Show More Hide
Publisher(s):
Impact Journals, LLC
Tags:
Medicine
Most Recent Tweet View All Tweets
article description
Previous studies suggest beta-adrenergic receptor (β-AR) antagonists (β-blockers) decrease breast cancer progression, tumor metastasis, and patient mortality; however the mechanism for this is unknown. Immunohistochemical analysis of normal and malignant breast tissue revealed overexpression of β1-AR and β3-AR in breast cancer. A retrospective cross-sectional study of 404 breast cancer patients was performed to determine the effect of β-blocker usage on tumor proliferation. Our analysis revealed that non-selective β-blockers, but not selective β-blockers, reduced tumor proliferation by 66% (p < 0.0001) in early stage breast cancer compared to non-users. We tested the efficacy of propranolol on an early stage breast cancer patient, and quantified the tumor proliferative index before and after treatment, revealing a propranolol-mediated 23% reduction (p = 0.02) in Ki67 positive tumor cells over a three-week period. The anti-proliferative effects of β-blockers were measured in a panel of breast cancer lines, demonstrating that mammary epithelial cells were resistant to propranolol, and that most breast cancer cell lines displayed dose dependent viability decreases following treatment. Selective β-blockers alone or in combination were not as effective as propranolol at reducing breast cancer cell proliferation. Molecular analysis revealed that propranolol treatment of the SK-BR-3 breast cancer line, which showed high sensitivity to beta blockade, led to a reduction in Ki67 protein expression, decreased phosphorylation of the mitogenic signaling regulators p44/42 MAPK, p38 MAPK, JNK, and CREB, increased phosphorylation of the cell survival/apoptosis regulators AKT, p53, and GSK3β. In conclusion, use of non-selective β-blockers in patients with early stage breast cancer may lead to decreased tumor proliferation.

This article has 0 Wikipedia mention.